Weiss Ratings upgraded Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, July 29th. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Get Amneal Pharmaceuticals alerts:Get Our Latest Report on Amneal PharmaceuticalsAmneal Pharmaceuticals Stock PerformanceShares of NASDAQ AMRX opened at $18.07 on Friday. As a group, analysts predict that Amneal Pharmaceuticals will post 0.92 earnings per share for the current year. Featured StoriesReceive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.